576 related articles for article (PubMed ID: 33984334)
1. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
2. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
5. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
[TBL] [Abstract][Full Text] [Related]
6. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
Liu J; Wang T; He K; Xu M; Gong JP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
[TBL] [Abstract][Full Text] [Related]
7. Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.
Kim SH; Kim G; Han DH; Lee M; Kim I; Kim B; Kim KH; Song YM; Yoo JE; Wang HJ; Bae SH; Lee YH; Lee BW; Kang ES; Cha BS; Lee MS
Autophagy; 2017 Oct; 13(10):1767-1781. PubMed ID: 28933629
[TBL] [Abstract][Full Text] [Related]
8. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release.
Pan J; Ou Z; Cai C; Li P; Gong J; Ruan XZ; He K
Cell Immunol; 2018 Oct; 332():111-120. PubMed ID: 30103942
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid improves hepatic steatosis and inflammation by inhibiting NLRP3 inflammasome activation.
Yang ZY; Liu F; Liu PH; Guo WJ; Xiong GY; Pan H; Wei L
Int J Clin Exp Pathol; 2017; 10(8):8119-8129. PubMed ID: 31966664
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit.
Flores-Costa R; Duran-Güell M; Casulleras M; López-Vicario C; Alcaraz-Quiles J; Diaz A; Lozano JJ; Titos E; Hall K; Sarno R; Masferrer JL; Clària J
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28263-28274. PubMed ID: 33106416
[TBL] [Abstract][Full Text] [Related]
13. Restraint stress promotes nonalcoholic steatohepatitis by regulating the farnesoid X receptor/NLRP3 signaling pathway.
Yang F; Lv XT; Lin XL; Wang RH; Wang SM; Wang GE
Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1961-1971. PubMed ID: 37997375
[TBL] [Abstract][Full Text] [Related]
14. CXCL5 promotes lipotoxicity of hepatocytes through upregulating NLRP3/Caspase-1/IL-1β signaling in Kupffer cells and exacerbates nonalcoholic steatohepatitis in mice.
Qi J; Yan X; Li L; Qiu K; Huang W; Zhou Z
Int Immunopharmacol; 2023 Oct; 123():110752. PubMed ID: 37573690
[TBL] [Abstract][Full Text] [Related]
15. The TIR/BB-loop mimetic AS-1 prevents non-alcoholic steatohepatitis and hepatic insulin resistance by inhibiting NLRP3-ASC inflammasome activation.
Wang X; Gao Y; Song J; Tang C; Wang M; Que L; Liu L; Zhu G; Chen Q; Yao Y; Xu Y; Li J; Li Y
Br J Pharmacol; 2017 Jun; 174(12):1841-1856. PubMed ID: 28306139
[TBL] [Abstract][Full Text] [Related]
16. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
Sui YH; Luo WJ; Xu QY; Hua J
World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
Liu SY; Huang CC; Yang YY; Huang SF; Lee TY; Li TH; Hou MC; Lin HC
PLoS One; 2022; 17(12):e0276717. PubMed ID: 36490253
[TBL] [Abstract][Full Text] [Related]
18. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
Gaul S; Leszczynska A; Alegre F; Kaufmann B; Johnson CD; Adams LA; Wree A; Damm G; Seehofer D; Calvente CJ; Povero D; Kisseleva T; Eguchi A; McGeough MD; Hoffman HM; Pelegrin P; Laufs U; Feldstein AE
J Hepatol; 2021 Jan; 74(1):156-167. PubMed ID: 32763266
[TBL] [Abstract][Full Text] [Related]
20. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.
Zhang NP; Liu XJ; Xie L; Shen XZ; Wu J
Lab Invest; 2019 Jun; 99(6):749-763. PubMed ID: 30700851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
